THE WIRE · № 82326
TANEA "REBEL" BROOKS STEPS UP HER LEADERSHIP ROLE, JOINING I AM ALS AS HONORARY BOARD MEMBER FOLLOWING SENATE PASSAGE OF ACT FOR ALS
01 THE MACHINE READ
WHY IT MATTERS.
ALS legislation extension supports research funding, a slow-moving positive for ALS-focused biotech but no direct ticker catalyst.
ALS funding extension, slow healthcare tailwind
Appropriations and trial progress
Funding may not convert to approved therapies
FULL DISPATCH
I AM ALS Ambassador and Former AEW Star Living with ALS Recognized for Her Advocacy as Congress Unanimously Passes Extension of the Landmark ALS Legislation, Co-Written By I AM ALS Co-Founder Brian Wallach Bill Passage Means Five More Years To Scale Research Infrastructure and Treatment...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs, BsAbs, CAR-Ts, Aurora Kinase Inhibitors, and EZH2 Inhibitors2026-10-15 14:31 UTC
Iambic Therapeutics sets $16 IPO price, targets $150 million raise2026-10-15 11:55 UTC
Odacova Health Unveils Nine-Year Canine Longevity Study at ALOS 2026, Charting a New Path to Extend Pet Healthspan2026-10-15 12:32 UTC
Expression Therapeutics Awarded NCI SBIR Grant to Advance ET501, a PTK7-Targeted γδ T-Cell Therapy for Children with High-Risk Neuroblastoma2026-10-15 13:05 UTC
Heart implant maker BioVentrix withdraws plans for Nasdaq IPO2026-10-15 13:56 UTC
Lilly confirms date and conference call for third-quarter 2026 financial results announcement2026-10-15 14:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.